459 related articles for article (PubMed ID: 21330939)
1. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.
McCannel CA
Retina; 2011 Apr; 31(4):654-61. PubMed ID: 21330939
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Fileta JB; Scott IU; Flynn HW
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(2):143-9. PubMed ID: 24635156
[TBL] [Abstract][Full Text] [Related]
3. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
[TBL] [Abstract][Full Text] [Related]
7. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
[TBL] [Abstract][Full Text] [Related]
8. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
Inman ZD; Anderson NG
Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
[TBL] [Abstract][Full Text] [Related]
9. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
[TBL] [Abstract][Full Text] [Related]
11. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
[TBL] [Abstract][Full Text] [Related]
13. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
14. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
Casparis H; Wolfensberger TJ; Becker M; Eich G; Graf N; Ambresin A; Mantel I; Michels S
Retina; 2014 Jan; 34(1):12-7. PubMed ID: 23945639
[TBL] [Abstract][Full Text] [Related]
15. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome.
Dossarps D; Bron AM; Koehrer P; Aho-Glélé LS; Creuzot-Garcher C;
Am J Ophthalmol; 2015 Jul; 160(1):17-25.e1. PubMed ID: 25892127
[TBL] [Abstract][Full Text] [Related]
16. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
Forooghian F; Albiani DA; Kirker AW; Merkur AB
Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
[TBL] [Abstract][Full Text] [Related]
17. Acute endophthalmitis after intravitreal injection and preventive effect of preoperative topical antibiotics.
Park Y; Kim KS; Park YH
J Ocul Pharmacol Ther; 2013 Dec; 29(10):900-5. PubMed ID: 24067061
[TBL] [Abstract][Full Text] [Related]
18. The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection.
Storey P; Dollin M; Rayess N; Pitcher J; Reddy S; Vander J; Hsu J; Garg S;
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):235-42. PubMed ID: 25940556
[TBL] [Abstract][Full Text] [Related]
19. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics.
Li AL; Wykoff CC; Wang R; Chen E; Benz MS; Fish RH; Wong TP; Major JC; Brown DM; Schefler AC; Kim RY; OʼMalley RE
Retina; 2016 Jul; 36(7):1349-56. PubMed ID: 26655622
[TBL] [Abstract][Full Text] [Related]
20. Effect of a Strict 'No-Talking' Policy During Intravitreal Injection on Post-Injection Endophthalmitis.
Garg SJ; Dollin M; Hsu J; Storey P; Vander JF
Ophthalmic Surg Lasers Imaging Retina; 2015; 46(10):1028-34. PubMed ID: 26599245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]